Dyslipidemia

Type: Keyphrase
Name: Dyslipidemia
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

New Findings from Department of Nephrology Update Understanding of Antineoplastics (More Potent Lipid-Lowering Effect by Rosuvastatin Compared With...

New Findings from Department of Nephrology Update Understanding of Antineoplastics (More Potent Lipid-Lowering Effect by Rosuvastatin Compared With Fluvastatin in Everolimus-Treated Renal Transplant Recipients)By a News Reporter-Staff News Editor at Biotech ... [Published HispanicBusiness.com - Jul 24 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 5 reports

Amgen's Evolocumab is Set to Become the Clinical Gold-Standard Among Statin Add-On Therapies for Dyslipidemia

Other key findings from the DecisionBase report entitled : Comments from Research Associate Stefanie Hoffart, M. Sc.: Ms. Hoffart has written a blog on the subject, which can be found here.About Decision Resources GroupDecision Resources Group offers ... [Published Wall Street Select - Jul 21 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

Reports from C.N. Ferreira et al Highlight Recent Findings in Vascular Diseases (Hyper-coagulable profile with elevated pro-thrombotic biomarkers and...

Reports from C.N. Ferreira et al Highlight Recent Findings in Vascular Diseases (Hyper-coagulable profile with elevated pro-thrombotic biomarkers and increased cerebro- and cardio-vascular disease risk exist among healthy dyslipidemic women)By a News ... [Published 4 Traders - Jul 16 2014]
First reported Jul 09 2014 - Updated Jul 10 2014 - 1 reports

Dezima Extends Clinical Development of Dyslipidemia Drug

Dezima Pharma, the biotechnology company developing innovative drugs in the field of dyslipidemia, announced the approval of a Phase 1 pilot study in subjects with isolated, elevated Lipoprotein(a) (Lp(a)), for which additional funding has been secur ... [Published Drug Discovery and Development - Jul 09 2014]
First reported Jun 30 2014 - Updated Jul 01 2014 - 2 reports

Synageva BioPharma reports positive top-line results from Phase III study of Sebelipase Alfa

Synageva BioPharma (Nasdaq: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, has announced that the global, randomized, double-blind, placebo-controlled Phase III ARISE trial of sebelipase alfa met the primary endpoint ... [Published Pharma Letter - Jul 01 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Watch and learn: These videos can save you from killer diseases

[embedded content]Non-communicable diseases such as hypertension, cardio vascular disease, stroke and diabetes are considered the top killing diseases amongst Filipinos. These illnesses are lifestyle diseases primarily caused by sedentary and unhealthy ... [Published Interaksyon - Jul 01 2014]
First reported Jun 27 2014 - Updated Jun 27 2014 - 2 reports

Research and Markets: Product and Pipeline Analysis of the Global Therapeutic Lipid Modulators Market

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/dk238k/product_and) has announced the addition of the "Product and Pipeline Analysis of the Global Therapeutic Lipid Modulators Market" report to their offering. ... [Published Business Wire Health News - Jun 27 2014]
Entities: Lipid, Pipeline, Market
First reported Jun 24 2014 - Updated Jun 24 2014 - 1 reports

Prevalence, Treatment, and Control of Dyslipidemia and Hypertension in 4278 HIV Outpatients

Objective: Patients with HIV may have an increased risk of cardiovascular disease (CVD). The objective of this study was to determine the prevalence, treatment, and control of low-density lipoprotein cholesterol (LDL-C) dyslipidemia and hypertension in ... [Published JAIDS - Jun 24 2014]
First reported Jun 03 2014 - Updated Jun 03 2014 - 1 reports

Mixed Dyslipidemia Global Clinical Trials Review, H1, 2014

NEW YORK, June 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:Mixed Dyslipidemia Global Clinical Trials Review, H1, 2014... ... [Published PR Newswire: Health - Jun 03 2014]
First reported May 28 2014 - Updated May 28 2014 - 1 reports

Research and Markets: Mixed Dyslipidemia Global Clinical Trials Review, H1, 2014

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/s8k8lc/mixed) has announced the addition of the "Mixed Dyslipidemia Global Clinical Trials Review, H1, 2014" report to their offering. Our clinical trial report, ... [Published Business Wire Professional Services News - May 28 2014]
First reported May 01 2014 - Updated May 01 2014 - 3 reports

The National Lipid Association Releases Draft Recommendations for Patient-Centered Treatment of Dyslipidemia

ORLANDO, Fla.--(EON: Enhanced Online News)--The National Lipid Association recently convened an Expert Panel to draft a document that would serve as guidance to clinicians for treating patients with dyslipidemia. ... [Published EON Science - May 01 2014]
Entities: Lipid, Dyslipidemia
First reported May 01 2014 - Updated May 01 2014 - 1 reports

Data Showed After 52 Weeks, LIVALO® (pitavastatin) 4 mg Maintained Similar Safety and Significantly Greater LDL-C Reduction Compared with Pravastatin 40 mg in HIV-infected Adults with Dyslipidemia

ORLANDO, Fla., May 1, 2014 /PRNewswire/ -- Kowa Pharmaceuticals America, Inc. announced results of a pre-specified safety analysis from the INTREPID (HIV-infected patieNts and TREatment with PItavastatin vs. pravastatin for Dyslipidemia) trial evaluating ... [Published PR Newswire: General Business - May 01 2014]

Quotes

According to the news editors, the research concluded: "The combination of everolimus/rosuvastatin seems to be as safe as the everolimus/fluvastatin combination."
...need for additional lipid-lowering treatment when the risk of cardiovascular disease remains clinically significant is still widely recognized. "Of the evaluated emerging therapies for statin-treated patients, the PCSK9 inhibitors carry the highest potential to have a positive impact on cardiovascular outcomes, although it is likely that they will initially only be approved for small niche populations. In addition, the expected high price of these agents will limit access."
According to the news editors, the research concluded: " Hyper -coagulability was not associated with dyslipidemia, but was correlated with the female gender, which might pose an increased thromboembolic risk in asymptomatic women."
"I think this change is important, that we now have a brand-new risk assessment tool," said Morris. "For decades we've been using different iterations of"

More Content

All (36) | News (21) | Reports (0) | Blogs (11) | Audio/Video (0) | Fact Sheets (4) | Press Releases (0)
sort by: Date | Relevance
New Findings from Department of Nephrology Upda... [Published HispanicBusiness.com - Jul 24 2014]
Amarin: Will The Lamb Of Ireland Bleat Or The L... [Published Seeking Alpha - Jul 21 2014]
Amgen's Evolocumab is Set to Become the Clinica... [Published Wall Street Select - Jul 21 2014]
Amgen's Evolocumab is Set to Become the Clinica... [Published BioSpace - Jul 21 2014]
Amgen's Evolocumab is Set to Become the Clinica... [Published Nasdaq - Jul 21 2014]
Amgen's Evolocumab is Set to Become the Clinica... [Published RCL Advisors - Jul 21 2014]
Amgen's Evolocumab is Set to Become the Clinica... [Published PR Newswire: Entertainment & Media - Jul 21 2014]
Reports from C.N. Ferreira et al Highlight Rece... [Published 4 Traders - Jul 16 2014]
Dezima Extends Clinical Development of Dyslipid... [Published Drug Discovery and Development - Jul 09 2014]
Dezima Pharma Extends Clinical Development Prog... [Published BioSpace - Jul 09 2014]
Land of Confusion: Sifting Through the Choleste... [Published American Journal of Public Health - Jul 09 2014]
Synageva BioPharma reports positive top-line re... [Published Pharma Letter - Jul 01 2014]
Watch and learn: These videos can save you from... [Published Interaksyon - Jul 01 2014]
FDA Approves MannKind's Afrezza; Synageva BioPh... [Published BioMedReports - Jul 01 2014]
Synageva BioPharma™ Reports Positive Top-Line R... [Published BusinessWeek - Jun 30 2014]
Synageva BioPharma™ Reports Positive Top-Line R... [Published ADVFN India - Jun 30 2014]
Research and Markets: Product and Pipeline Anal... [Published Business Wire Health News - Jun 27 2014]
Product and Pipeline Analysis of the Global The... [Published Individual.com - Jun 27 2014]
New National Diabetes Statistics Report Released [Published Caribbean Today - Jun 25 2014]
Prevalence, Treatment, and Control of Dyslipide... [Published JAIDS - Jun 24 2014]
Piramal’s NCE Research shared Preclinical effic... [Published Noodls - Jun 18 2014]
Mixed Dyslipidemia Global Clinical Trials Revie... [Published PR Newswire: Health - Jun 03 2014]
Research and Markets: Mixed Dyslipidemia Global... [Published Business Wire Professional Services News - May 28 2014]
Viking Signs Broad Licensing Deal With Ligand P... [Published Marketwire - Breaking News Releases - May 22 2014]
Research and Markets: Dyslipidemia - Pipeline R... [Published Business Wire Health News - May 07 2014]
The National Lipid Association Releases Draft R... [Published EON Science - May 01 2014]
The National Lipid Association Releases Draft R... [Published Business Wire Science: Science News - May 01 2014]
The National Lipid Association Releases Draft R... [Published Business Wire Health News - May 01 2014]
Data Showed After 52 Weeks, LIVALO® (pitavastat... [Published PR Newswire: General Business - May 01 2014]
Methods of treating mixed dyslipidemia [Published PharmCast - Apr 08 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Amgen's Evolocumab is Set to Become the Clinica... [Published PR Newswire: Entertainment & Media - Jul 21 2014]
BURLINGTON, Mass., July 21, 2014 /PRNewswire/ -- Decision Resources Group finds that Amgen's evolocumab (AMG-145) is set to become the clinical gold-standard among statin add-on therapies used to treat patients with dyslipidemia. The competitive advantages ...
Research and Markets: Product and Pipeline Anal... [Published Business Wire Health News - Jun 27 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/dk238k/product_and) has announced the addition of the "Product and Pipeline Analysis of the Global Therapeutic Lipid Modulators Market" report to their offering. ...
Mixed Dyslipidemia Global Clinical Trials Revie... [Published PR Newswire: Health - Jun 03 2014]
NEW YORK, June 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:Mixed Dyslipidemia Global Clinical Trials Review, H1, 2014... ...
Research and Markets: Mixed Dyslipidemia Global... [Published Business Wire Professional Services News - May 28 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/s8k8lc/mixed) has announced the addition of the "Mixed Dyslipidemia Global Clinical Trials Review, H1, 2014" report to their offering. Our clinical trial report, ...
Viking Signs Broad Licensing Deal With Ligand P... [Published Marketwire - Breaking News Releases - May 22 2014]
Ligand to Invest $2.5 Million to Support Development of Novel Treatments for Diabetes, Cancer Cachexia, Dyslipidemia and Anemia ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.